Medicine Press release

Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada) and Eisai (Headquarters: Tokyo, CEO: Haruo Naito) today announced the first presentation of results from the Phase 3 LITESPARK-011 trial evaluating the dual oral regimen of WELIREG(R) (belzutifan), Merck & Co., Inc., Rahway, NJ, USA's first-in-class oral hypoxiainducible factor-2 alpha (HIF-2a) inhibitor, plus LENVIMA(R) (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of patients with advanced renal cell carcinoma (RCC) whose disease progressed on or after treatment with anti-programmed death receptor-1 (PD-1)/ programmed death-ligand 1 (PD-L1) therapy.
More info..

Everest Medicines shareholders passed all proposed resolutions at an extraordinary general meeting (the 'EGM') held virtually on February 24, 2026, the company said in a filing.
More info..

Everest Medicines shareholders passed all proposed resolutions at an extraordinary general meeting (the 'EGM') held virtually on February 24, 2026, the company said in a filing.
More info..

Japan Community Healthcare Organization Osaka Hospital (JCHO Osaka Hospital), Fujitsu Japan Limited, and Fortience Consulting Inc. today announced the commencement of a project aimed at establishing a system for the safe utilization of generative AI across all medical operations at JCHO Osaka Hospital.
More info..

Bioxytran, Inc., a biotechnology company developing galectin-targeting carbohydrate technologies with applications across infectious disease, metabolic health, and inflammation, today announced that it has entered into a commercial Distribution Agreement with Khoury Medical LTD ("Khoury Medical"), a company focused on the development and commercialization of plant-derived dietary supplements.
More info..

Bioxytran, Inc., a biotechnology company developing galectin-targeting carbohydrate technologies with applications across infectious disease, metabolic health, and inflammation, today announced that it has entered into a commercial Distribution Agreement with Khoury Medical LTD ("Khoury Medical"), a company focused on the development and commercialization of plant-derived dietary supplements.
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received an orphan drug designation for its in-house discovered and developed novel selective orexin 2 receptor agonist E2086, with prospective indication for narcolepsy, from the Ministry of Health, Labour and Welfare (MHLW).
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received an orphan drug designation for its in-house discovered and developed novel selective orexin 2 receptor agonist E2086, with prospective indication for narcolepsy, from the Ministry of Health, Labour and Welfare (MHLW).
More info..

Meiji Co., Ltd. and Fujitsu Limited today announced the start of a pilot project towards the social implementation of rRAFU(TM) [1] (Rapid Risk Assessment Tool for Future Undernutrition Status), the world's first [2] indicator to predict future risks of malnutrition and frailty (developed by Meiji.) The pilot will focus on residents aged 60 and over in Kawasaki City, Kanagawa Prefecture.
More info..

Meiji Co., Ltd. and Fujitsu Limited today announced the start of a pilot project towards the social implementation of rRAFU(TM) [1] (Rapid Risk Assessment Tool for Future Undernutrition Status), the world's first [2] indicator to predict future risks of malnutrition and frailty (developed by Meiji.) The pilot will focus on residents aged 60 and over in Kawasaki City, Kanagawa Prefecture.
More info..